Mabion (MAB) investor relations material

Company overview and strategy

• Operates as a biologics-focused CDMO with 19 years of experience in developing and manufacturing biological medicines, offering comprehensive services from cell line development to commercial manufacturing.

• Holds GMP and ISO certifications, with a modern, scalable production infrastructure and over 200 qualified professionals.

• Implements a 2025-2030 strategy focused on technology, operational excellence, and portfolio diversification, aiming to become a leading innovation champion in Central and Eastern Europe.

• Expands into next-generation biologics, including ADCs and ATMPs, and leverages co-development partnerships and selective innovation.

• Targets high-growth segments and global markets, with a focus on unmet medical needs and cost-effective solutions.

Financial performance and outlook

• Achieved over PLN 350 million in CDMO revenues from Q4 2021 to Q2 2024, but recent revenues are not yet sufficient to cover operating costs, with a current cash burn rate of PLN 15 million.

• Cash position at PLN 6.6 million as of Q1 2026, supplemented by nearly PLN 40 million in bridge financing from multiple lenders.

• Active sales pipeline with 33 open sales processes and probability-weighted bids valued at USD 51.6 million as of May 2026.

• Strategic goal to reach break-even and profitability by the end of 2026, with anticipated annual revenues exceeding PLN 100 million in the coming years.

• Revenue sources are expected to diversify across process development, analytics, and drug substance production.

Market positioning and competitive advantages

• Recognized for scientific excellence, quality, and competitive cost base, with a proven track record including global clients such as Novavax.

• Winner of the 2025 International CDMO Leadership Award in Biologics.

• Infrastructure allows for 40-50% capacity expansion without major capital expenditure.

• Positioned to benefit from favorable CDMO market trends, including increased outsourcing, complexity of biologics, and growing demand for integrated services.

• Expanded geographic reach to Europe, MENA, Asia, and the USA, targeting emerging and mid-size biotech clients.